KVD900 300 mg clinical trials

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

This study is looking into the long-term safety of a new medication, KVD900 (Sebetralstat), for teenagers and adults with Hereditary Angioedema (HAE). It is an extension of a previous study, continuing to monitor participants who have already been taking the drug.